Browsing by Author "Maris, JM"
Now showing items 1-2 of 2
-
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study
Maris, JM; Reisfeld, RA; Gadbaw, B; Hecht, T; Cohn, SL; DeSantes, KB; Eickhoff, J; Gan, J; Wagner, B; Albertini, MR; Kimball, J; Reynolds, CP; Seeger, RC; Voss, SD; Hank, JA; Gillies, SD; London, WB; Shusterman, S; Sondel, PM (2010-11-20)PURPOSE: The hu14.18-IL2 fusion protein consists of interleukin-2 molecularly linked to a humanized monoclonal antibody that recognizes the GD2 disialoganglioside expressed on neuroblastoma cells. This phase II study ... -
Genotypes of NK cell KIR Receptors, Their Ligands, and Fc? Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy
Maris, JM; Seeger, RC; London, WB; DeSantes, KB; Gadbaw, B; Yang, R; Reisfeld, RA; Gillies, SD; Shusterman, S; Kim, K; Seo, S; Gan, J; Lorentzen, D; Kolesar, J; Hank, JA; Delgado, DC; Sondel, Paul (2010-12-01)Response to immunocytokine (IC) therapy is dependent on natural killer cells in murine neuroblastoma (NBL) models. Furthermore, killer immunoglobulin-like receptor (KIR)/KIR-ligand mismatch is associated with improved ...